STOCK TITAN

Revelation Biosciences (REVB) Financials

REVB NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$12.2M n/m YoY
EPS (Diluted) -$23.95 FY2025 annual
Operating Cash Flow -$10.1M n/m YoY
Market Cap $2.0M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.3x on $7.2M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the REVB SEC filings page.

This page shows Revelation Biosciences, Inc. (REVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI REVB FY2025

The figures describe a research-led company funded externally, with 2025 losses closely tracking cash use and a less burdened balance sheet.

In FY2025, the net loss was $8.9M against operating cash flow of -$8.3M, showing accounting losses and cash consumption were closely aligned. FY2024 paired a net loss of $15.0M with operating cash flow of -$18.3M, so the narrower gap in FY2025 indicates improved earnings-to-cash alignment rather than a change to profitability.

The 2025 expense base is concentrated in research and development of $4.1M and selling, general and administrative costs of $5.0M. Together, those costs were nearly the same scale as the $9.1M operating loss, making the current economics development-led rather than driven by operating leverage.

External financing remains central: FY2025 financing cash flow was $12.5M against operating cash flow of -$8.3M. Liabilities represented 23.5% of assets, down from 28.9% in FY2024, while the current ratio reached 5.4x; the supplied liquidity comparison equaled 15.5 months of the latest reported annual operating outflow.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Revelation Biosciences, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
3/6

Revelation Biosciences, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Revelation Biosciences, Inc. reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$3.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Revelation Biosciences, Inc.'s EBITDA was -$3.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$3.3M
YoYn/m
QoQn/m
5Y CAGRn/m

Revelation Biosciences, Inc. reported a net loss of $3.3M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$5.92

Revelation Biosciences, Inc. earned -$5.92 per diluted share (EPS) in Q3 2026.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$2.4M
QoQn/m

Revelation Biosciences, Inc. recorded an outflow of $2.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$9.1M
YoY-28.2%
QoQ-20.6%
5Y CAGR+17.1%

Revelation Biosciences, Inc. held $9.1M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
683,442

Revelation Biosciences, Inc. had 683,442 shares outstanding in Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-45.8%
YoY-28.5pp
QoQ-12.8pp

Revelation Biosciences, Inc.'s quarterly ROE was -45.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 28.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$1.5M
YoY+63.9%
QoQ-21.1%
5Y CAGR-0.3%

Revelation Biosciences, Inc. invested $1.5M in research and development in Q3 2026. This represents an increase of 63.9% from the same quarter a year earlier. Against the prior quarter it is down 21.1%.

Capital Expenditures
$0
QoQ-100.0%

Revelation Biosciences, Inc. reported no capital expenditure in Q3 2026. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

REVB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REVB quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$1.5M+63.9%$1.9M+45.6%$1.4M+60.3%$964K+59.2%$923K+11.1%$1.3M-5.5%$859K+19.7%$606K-42.9%
SG&A Expenses$1.9M+83.4%$1.7M+52.5%$1.7M+38.8%$1.6M+40.0%$1.0M+5.6%$1.1M+1.4%$1.2M+4.4%$1.1M-9.3%
Operating Income-$3.4Mn/m-$3.7Mn/m-$3.1Mn/m-$2.6Mn/m-$1.9Mn/m-$2.5Mn/m-$2.1Mn/m-$1.8Mn/m
EBITDA-$3.4Mn/m-$3.7Mn/m-$3.1Mn/m-$2.6Mn/m-$1.9Mn/m-$2.5Mn/m-$2.1Mn/m-$1.7Mn/m
Income Tax$0n/mN/AN/AN/A$0n/mN/A$0n/m$0n/m
Net Income-$3.3Mn/m-$3.3Mn/m-$3.0Mn/m-$2.5Mn/m-$1.9Mn/m-$2.4Mn/m-$2.1Mn/m-$1.7Mn/m
EPS (Basic)-$5.92-$0.87-$2.71N/A-$49.51n/m-$28.04-$25.34n/mN/A
EPS (Diluted)-$5.92-$0.87-$2.71N/A-$49.51n/m-$28.04-$25.34n/mN/A
Diluted Shares (Avg)559,5964M3MN/A94,455+69.2%200,66880,943+18.8%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

REVB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REVB quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'25FilingQ1'25FilingQ4'2410-K
Total Assets$10.0M-22.0%$12.5M+131.7%$15.0M+278.9%$11.6M+74.9%$12.9M+90.7%$5.4M-56.0%$4.0M-73.0%$6.6M-45.8%
Current Assets$9.3M-27.8%$11.7M+118.0%$14.2M+261.7%$10.8M+64.7%$12.8M+92.7%$5.4M-56.1%$3.9M-73.1%$6.6M-46.0%
Cash & Equivalents$9.1M-28.2%$11.5M+121.9%$14.1M+281.0%$10.7M+64.6%$12.7M+94.3%$5.2M-57.1%$3.7M-74.5%$6.5M-45.8%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$2.8M+50.4%$2.4M+54.9%$2.1M+88.6%$2.7M+42.2%$1.9M-54.4%$1.6M-85.9%$1.1M-79.2%$1.9M-65.6%
Current Liabilities$2.3M+25.5%$1.9M+19.8%$1.4M+30.1%$2.0M+4.4%$1.9M-54.4%$1.6M-85.9%$1.1M-79.2%$1.9M-65.6%
Non-Current Liabilities$461Kn/m$551Kn/m$638Kn/m$724Kn/m$0n/m$0n/m$0n/m$0n/m
Total Equity$7.2M-34.3%$10.1M+163.1%$13.0M+350.9%$8.9M+88.2%$11.0M+311.5%$3.8M+235.5%$2.9M-69.6%$4.7M-29.2%
Retained Earnings-$59.1Mn/m-$55.8Mn/m-$52.4Mn/m-$49.4Mn/m-$46.9Mn/m-$45.0Mn/m-$42.6Mn/m-$40.5Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

REVB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REVB quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$2.4Mn/m-$2.6Mn/m-$3.2Mn/m-$2.0Mn/m-$1.6Mn/m-$1.9Mn/m-$2.8Mn/m-$3.7Mn/m
Depreciation & Amortization$8K+21.0%$8K+15.1%$7K-0.2%$6K-19.0%$7K-6.3%$7K0.0%$7K+15.3%$7K+15.3%
Stock-Based Compensation$482K+55074.9%$401K+45881.3%$471K+110.8%N/A$874-97.3%$873-97.3%$223K+596.3%N/A
Capital Expenditures$0$40K$72KN/AN/AN/AN/AN/A
Free Cash Flow-$2.4M-$2.6M-$3.3MN/AN/AN/AN/AN/A
Investing Cash Flow$0-$40K-$72KN/AN/AN/AN/A$18K
Financing Cash Flow$0-100.0%-$34K$6.7M-$41K-101.1%$9.1M+143.8%N/AN/A$3.7Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

REVB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REVB quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-45.8%-28.5pp-33.0%+30.9pp-23.2%+48.0pp-28.3%+8.3pp-17.3%+66.5pp-63.9%+671.8pp-71.2%-42.9pp-36.6%-3.5pp
Return on Assets-33.1%-18.3pp-26.6%+18.7pp-20.0%+31.7pp-21.7%+4.4pp-14.8%+18.4pp-45.3%+23.1pp-51.7%-33.4pp-26.1%-8.0pp
Current Ratio3.98-2.9x6.21+2.8x10.02+6.4x5.41+2.0x6.92+5.3x3.42+2.3x3.61+0.8x3.43+1.2x
Liabilities-to-Equity0.39+0.2x0.24-0.2x0.16-0.2x0.31-0.1x0.17-1.4x0.41-9.3x0.38-0.2x0.41-0.4x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Revelation Biosciences, Inc. REVB FY2025 N/A -$8.9M N/A $2.0M —
Jupiter Neurosciences, Inc. JUNS FY2025 $22K -$8.6M N/A $1.6M —
KALA BIO, Inc. KALA FY2025 $0 -$27.0M N/A $1.7M —
Purple Biotech Ltd. PPBT FY2025 N/A -$26.4M N/A $2.5M —
Clearmind Medicine Inc. CMND FY2025 N/A -$3.9M N/A $1.3M —
Calidi Biotherapeutics, Inc. CLDI FY2025 N/A -$19.9M N/A $1.6M —

Frequently Asked Questions

No, Revelation Biosciences, Inc. (REVB) reported a net loss of $12.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $8.9M.

Revelation Biosciences, Inc. (REVB) reported diluted earnings per share of -$23.95 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Revelation Biosciences, Inc. (REVB) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Revelation Biosciences, Inc. (REVB) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Revelation Biosciences, Inc. (REVB) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Revelation Biosciences, Inc. (REVB) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Revelation Biosciences, Inc. (REVB) invested $4.1M in research and development during fiscal year 2025.

Revelation Biosciences, Inc. (REVB) had 4M shares outstanding as of fiscal year 2025.

Revelation Biosciences, Inc. (REVB) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.

Revelation Biosciences, Inc. (REVB) had a liabilities-to-equity ratio of 0.31 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Revelation Biosciences, Inc. (REVB) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Revelation Biosciences, Inc. (REVB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $2.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Revelation Biosciences, Inc. (REVB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Revelation Biosciences, Inc. (REVB) held $10.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.3M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Revelation Biosciences, Inc. (REVB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Revelation Biosciences, Inc. (REVB) reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top